Coronavirus Response



When COVID-19 hit, scientists in the King Lab leveraged partnerships with UW virologists and vaccine researchers at the National Institutes of Health to quickly create promising vaccine candidates. Our lead nanoparticle vaccine candidate induces ten-fold more protective antibodies in animal testing than comparable vaccines that do not use IPD technology. It has now been transferred to multiple commercial partners. Human clinical trials are underway.

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2  |  Cell

The Dream Vaccine  |  Science


In less than a month, IPD researchers designed on the computer over two million minibinder proteins to target the novel coronavirus. Over 120,000 of the most promising candidates have been tested in the lab. The current best minibinders neutralize live virus with activities rivaling the best known antibodies. We are now working to advance these candidate antivirals into clinical testing.

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors  |  Science

Antibodies Good. Machine-Made Molecules Better?  |  New York Times


Diagnostic tests are essential for detecting coronavirus infection and immunity, but current tests are expensive and complex to perform. To overcome this, scientists in the Baker Lab have created new ways to detect SARS-CoV-2 in blood, as well as protective antibodies against it. These diagnostic biosensors are currently being optimized for use without laboratory instruments or refrigeration.

De novo design of modular and tunable protein biosensors  |  Nature


Join us

Our ability to meet the demands of the COVID-19 crisis is due in part to early supporters, leadership funding from the Bill & Melinda Gates Foundation, and the recent, transformative investment from The Audacious Project. Visionary philanthropists can still help provide the resources to continue advancing our COVID-19 response. 

If you would like to make a gift to support the Institute for Protein Design, please contact Katherine Cardinal, senior director for philanthropy, at 206.650.4503 or, Damien Chapman, director for corporate and foundation relations, at 206.616.4483 or, or Lance Stewart, chief strategy and operations officer, at 206.383.4187 or

“This outbreak has illustrated that it’s all hands on deck, and all of us together against the bugs. We are working with our collaborators at UW, the NIH, and the Bill & Melinda Gates Foundation to help create a safe and effective vaccine for not only SARS-CoV-2 but other coronaviruses as well.” Neil King, head of vaccine design at the IPD